Navigation Links
Michael Walton Retires From The Female Health Company Board of Directors
Date:9/10/2013

CHICAGO, Sept. 10, 2013 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the FC2 Female Condom, today announced that Michael R. Walton retired from its Board of Directors effective September 9, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

Mr. Walton, 76, elected to retire to reduce his workload.  He has been a director for 14 years and a long time supporter and early investor in FHCO.

O.B. Parrish, Chairman and CEO of The Female Health Company said: "Mike's participation on the Board and support over the years has contributed to the Company's success.  I have enjoyed working with Mike, and we will all miss working with him as a Board member."

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 143 other countries globally.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward‑looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update any forward‑looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward‑looking statements are inherently subject to known and unknown risks and uncertainties.  The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward‑looking statements.  Factors that may cause actual results to differ materially from those contemplated by such forward‑looking statements include, but are not limited to, the following:  product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10‑K for the fiscal year ended September 30, 2012.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.


'/>"/>
SOURCE The Female Health Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
2. Red Carpet Star Studded Celebrity Gala in Partnership with the Michael J. Fox Foundation for Parkinsons Research
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
5. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
6. Manhattan NYC Cosmetic Dentist Dr. Michael Wei Providing Invisalign Braces
7. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
8. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
9. Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
10. SurgiCount Medical Announces The Appointment Of Michael Roux As Vice President of Product Management
11. The Michael J. Fox Foundation Launches New Funding Opportunities for Parkinsons Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Stem cells are primitive cells found in ... the capacity to differentiate into mature cell types Stem ... first mouse embryonic stem cells were derived from embryos ... the first culturing of embryonic stem cells from non-human ... until 2006 As a result of these discoveries, stem ...
(Date:2/11/2016)... N.Y. , Feb. 11, 2016  Governor Andrew ... that will create 1,400 jobs throughout Western ... a partnership with the SUNY Polytechnic Institute, includes a ... Conventus Building in Buffalo , as ... foot manufacturing facility in Dunkirk . ...
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. (AIS) ... PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans and ... such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to ... Club, located in Norwalk, serves as the host site and directing the camps is ... “We have had successful camps in recent years around Des Moines and are fortunate ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Healthcare careers in ... five most searched jobs via the website of healthcare staffing leader Aureus Medical Group ... travel nurse jobs , travel therapy positions and in travel and direct ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... creating explosive growth in the field of long term care. With that, says ... for well-trained healthcare professionals in administrative roles in long term care environments. His ...
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not just ... PoppersTM series, sign language translation is featured in the top right of the screen. ... PoppersTM lessons has a sign language translator to teach kids the game and how ...
Breaking Medicine News(10 mins):